Retatrutide Cost: Current Pricing and What to Expect
Retatrutide costs $200-$500/month through compounding pharmacies in 2026. Compare pricing by access route, with projected brand-name costs after FDA approval.
Key takeaways
- Retatrutide has no commercial list price because it is not FDA-approved
- Compounding pharmacy pricing currently ranges from $250 to $500 per month
- Telehealth platforms offering retatrutide typically charge $200 to $400 monthly
- Projected brand-name pricing after FDA approval: $1,000 to $1,500 per month based on comparable drugs
- Insurance coverage is unavailable since no approved product exists
Pricing retatrutide right now is like pricing a car that hasn’t been released yet. There’s no manufacturer list price, no insurance formulary placement, and no generic competition. What does exist is a compounding pharmacy market that’s already filling demand for patients and providers who don’t want to wait for FDA approval.
Here’s what retatrutide actually costs through each available channel in 2026, and what you can expect when Eli Lilly eventually brings a commercial product to market.
Current pricing (2026)
Compounding pharmacy pricing
Compounding pharmacies are the primary source of retatrutide in 2026. These pharmacies prepare custom formulations under physician prescription, typically as lyophilized vials that patients reconstitute and inject.
| Monthly dose range | Estimated monthly cost |
|---|---|
| 2-4 mg/week (titration) | $150-$300 |
| 8-12 mg/week (maintenance) | $250-$500 |
Pricing varies significantly by pharmacy and region. Northeast and West Coast compounding pharmacies tend to charge on the higher end ($350-$650/month), while Southeast and Midwest pricing is more competitive ($250-$500) [source: industry pricing surveys, 2026].
Factors that affect compounding pharmacy pricing:
- Peptide purity and sourcing. Higher-purity API (active pharmaceutical ingredient) costs more to produce and verify
- Pharmacy type. 503A pharmacies prepare individual prescriptions; 503B outsourcing facilities can compound in larger batches, sometimes at lower cost
- Vial concentration and size. Larger vials with higher concentrations may be cheaper per milligram
Telehealth platform pricing
Several online peptide clinics and telehealth platforms now offer retatrutide. Their pricing typically bundles the consultation, prescription, and medication:
| What’s included | Estimated cost |
|---|---|
| Initial consultation | $100-$250 (one-time) |
| Monthly medication + follow-up | $200-$400 |
| Lab work (if required) | $100-$300 (periodic) |
Total first-month costs typically run $300-$650 including the initial consultation. Ongoing monthly costs settle to $200-$400 for the medication and provider oversight.
For perspective, compounded semaglutide currently costs $150-$400/month through similar channels, and compounded tirzepatide runs $200-$500/month. Retatrutide pricing falls in the same general range.
Clinical trial access
If you qualify for one of Eli Lilly’s TRIUMPH phase 3 trials, the medication is provided at no cost. Clinical trial participation also includes regular medical monitoring, lab work, and follow-up visits. Check ClinicalTrials.gov for active enrollment.
Projected brand-name pricing
When Eli Lilly brings retatrutide to market (projected late 2027 to early 2028), pricing will likely follow the pattern set by its existing products:
| Drug | Monthly list price |
|---|---|
| Mounjaro (tirzepatide) | ~$1,060/month |
| Zepbound (tirzepatide) | ~$1,060/month |
| Wegovy (semaglutide) | ~$1,350/month |
| Ozempic (semaglutide) | ~$935/month |
| Retatrutide (projected) | $1,000-$1,500/month |
These are list prices before insurance. With insurance coverage, out-of-pocket costs can range from $25 to $300/month depending on your plan. Without insurance, the full cost falls on the patient.
Eli Lilly has not announced retatrutide pricing. The projections above are based on the company’s existing GLP-1 products and the general trajectory of branded obesity medications.
Insurance and coverage
Currently, retatrutide is not covered by any insurance plan because it has no FDA approval. After approval, coverage will depend on:
FDA-approved indication. If approved for obesity, coverage may mirror current GLP-1 weight loss medications. Many insurance plans have expanded coverage for obesity treatments since 2024, though gaps remain. For more on insurance dynamics, see our guide on whether insurance covers peptide therapy.
Formulary placement. Even with FDA approval, insurers may require prior authorization, step therapy (trying cheaper alternatives first), or BMI documentation before covering retatrutide.
Employer plans. Large employer plans have been more willing to cover GLP-1 medications for weight loss than individual market plans.
How to reduce costs
For patients paying out of pocket now:
Compare compounding pharmacies. Pricing varies by $100-$200/month between pharmacies. Ask about bulk pricing for 3-month supplies.
Consider dose optimization. The clinical data shows that 8 mg produces 22.8% weight loss versus 24.2% at 12 mg. For some patients, the lower dose achieves sufficient results at a lower monthly cost [1].
Ask about vial concentrations. Higher-concentration vials (more milligrams per vial) typically cost less per dose than multiple lower-concentration vials.
Bundle with a telehealth provider. Some platforms offer lower per-month medication costs when bundled with longer subscription commitments.
Cost per pound of weight loss
An admittedly rough calculation, but useful for comparison:
Based on the phase 2 trial, participants on 12 mg lost an average of 58 pounds over 48 weeks (about 11 months) [1]:
| Access route | 11-month cost | Cost per pound lost |
|---|---|---|
| Compounding pharmacy ($375/mo avg) | $4,125 | ~$71/lb |
| Telehealth ($300/mo avg) | $3,300 | ~$57/lb |
| Projected brand-name ($1,250/mo avg) | $13,750 | ~$237/lb |
For comparison, Wegovy at $1,350/month with an average 35-pound loss over 68 weeks costs roughly $637 per pound lost. Retatrutide through compounding pharmacies is meaningfully cheaper per pound due to both lower cost and greater weight loss.
This comparison has obvious limitations: individual results vary, the brand-name price is projected, and “cost per pound” ignores the metabolic health benefits beyond weight alone.
Retatrutide cost vs. other weight loss medications
| Medication | Monthly cost (cash) | Monthly cost (insured) | Avg. weight loss |
|---|---|---|---|
| Retatrutide (compounded) | $200-$500 | N/A | 24-29% |
| Tirzepatide (Mounjaro/Zepbound) | $1,000-$1,100 | $25-$300 | 20-22% |
| Semaglutide (Wegovy) | $1,350 | $25-$300 | 15-17% |
| Compounded semaglutide | $150-$400 | N/A | 15-17% |
| Compounded tirzepatide | $200-$500 | N/A | 20-22% |
Compounded versions of all these medications are substantially cheaper than brand-name products. For more on this topic, see our guide on peptide therapy pricing.
Frequently asked questions
How much does retatrutide cost per month?▼
Through compounding pharmacies, retatrutide currently costs $250-$500 per month at maintenance doses (8-12 mg/week). Telehealth platforms offering bundled services charge $200-$400 monthly. These costs do not include initial consultations or lab work [2026 market data].
Will insurance cover retatrutide?▼
Not currently. Retatrutide has no FDA approval, so no insurance plans cover it. After potential approval in 2027-2028, coverage will depend on your specific plan, the approved indication, and insurer formulary decisions.
Is retatrutide cheaper than Mounjaro?▼
Compounded retatrutide ($200-$500/month) is cheaper than brand-name Mounjaro ($1,060/month list price). However, Mounjaro is FDA-approved with insurance coverage options that can reduce out-of-pocket costs significantly. Compounded Mounjaro/tirzepatide is priced similarly to compounded retatrutide.
Why is compounded retatrutide cheaper than brand-name GLP-1 drugs?▼
Compounding pharmacies purchase bulk peptide API and prepare individual prescriptions without the costs of large-scale clinical trials, FDA approval, marketing, and branded drug distribution. The trade-off is less regulatory oversight and no FDA-approved manufacturing process. See our guide on compounding pharmacy peptides for more detail.
How much will retatrutide cost when FDA-approved?▼
Based on Eli Lilly’s pricing for Mounjaro/Zepbound and Novo Nordisk’s pricing for Wegovy, brand-name retatrutide will likely cost $1,000-$1,500 per month at list price. Insurance could bring out-of-pocket costs down to $25-$300/month depending on coverage.
Is the cheapest retatrutide safe?▼
Price alone doesn’t determine quality, but extremely low pricing (under $100/month at full doses) should raise questions about peptide purity, source verification, and pharmacy legitimacy. Look for pharmacies that provide certificates of analysis (COA), use verified API sources, and operate under state pharmacy board oversight. For guidance, see our article on whether research peptides are safe.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Eli Lilly. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Press release. December 11, 2025.
- Peptide therapy cost trends and compounding pharmacy pricing data. Industry reports, 2025-2026.
- Novo Nordisk. Wegovy (semaglutide) prescribing information and pricing. 2024.
- Eli Lilly. Mounjaro (tirzepatide) prescribing information and pricing. 2024.
Get guides like this delivered weekly.
Evidence-based peptide research, protocol breakdowns, and provider reviews.
Get the Weekly Brief